ストックスクリーナーアプリを入手
8.86
2.85%
-0.26
アフターアワーズ：
9.17
0.31
+3.50%
前日終値:
$9.12
開ける：
$9.17
24時間の取引高:
1,231
Relative Volume:
0.54
時価総額：
$N/A
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-12.88%
1か月 パフォーマンス:
+1.96%
6か月 パフォーマンス:
-43.64%
1年 パフォーマンス:
-41.86%
1日の値動き範囲:
$8.86
$9.17
1週間の範囲:
$8.835
$10.01
52週間の値動き範囲:
$7.881
$16.27
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
CNCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
8.86 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
277.97 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
564.34 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
566.89 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
223.40 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
487.97 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf (CNCR) 最新ニュース
Exchange Traded Concepts to Close and Liquidate the Range Cancer Therapeutics ETF - The Joplin Globe
Learn to Evaluate (CNCR) using the Charts - news.stocktradersdaily.com
Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance
Cathie Wood Bets on Nvidia, AMD Despite Chip Curbs and Dumps Microsoft Stock - The Globe and Mail
Long Term Trading Analysis for (CNCR) - news.stocktradersdaily.com
From Panic to Positioning: Top ETFs to Watch After Asia’s Tariff Shock - The Globe and Mail
(CNCR) Investment Report - news.stocktradersdaily.com
10 Best Health Care Stocks to Buy for 2025 - US News Money
7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News
Best Stocks Under $20 Right Now - Benzinga
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - Nasdaq
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Nasdaq
QQQ ETF News, 3/19/2025 - The Globe and Mail
(CNCR) Proactive Strategies - Stock Traders Daily
Nasdaq Correction: Buy This Unstoppable ETF at a Discount - The Globe and Mail
Buffer ETFs to Consider for Protecting Gains and Limiting Losses - The Globe and Mail
S&P 500 Index Funds Yield Just 1.3%. Consider Buying These 2 Low-Cost Vanguard ETFs to Generate More Passive Income. - The Globe and Mail
VOO ETF News, 3/14/2025 - The Globe and Mail
VOO ETF News, 3/12/2025 - The Globe and Mail
Is the Fidelity High Dividend ETF the Smartest Investment You Can Make Today? - The Globe and Mail
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You? - The Globe and Mail
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy? - The Globe and Mail
SCHD ETF News, 3/11/2025 - The Globe and Mail
1 No-Brainer Artificial Intelligence (AI) ETF to Buy With $40 During the Nasdaq Sell-Off - The Globe and Mail
Why You Can Do Better Than the SPDR S&P 500 ETF Trust - The Globe and Mail
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Best Biotech Stocks to Buy in 2025 - The Motley Fool
(CNCR) Investment Analysis - news.stocktradersdaily.com
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Dividend Investing in Canada: Trends, Leaders, and ETF Picks - The Globe and Mail
N2OFF, Inc. Enters Agreement to Acquire MitoCareX Bio Ltd. to Expand Cancer Therapeutics Portfolio - Nasdaq
Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025 - Investing News Network
CIBC Asset Management announces CIBC ETF cash distributions for February 2025 - The Globe and Mail
(CNCR) Trading Signals - Stock Traders Daily
The Unstoppable Momentum in Oncology M&A - Nasdaq
2025 Outlook: Healthcare Technology & Innovation - ETF Trends
This Warren Buffett Index Fund Could Turn $400 Per Month Into $868,200 - The Globe and Mail
Psychedelic ETF PSIL Is 2025's Best-Performing ETF - etf.com
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Armenian Reporter
When (CNCR) Moves Investors should Listen - Stock Traders Daily
SELLAS Life Sciences Group, Inc. Secures $25 Million in Registered Direct Offering for Cancer Therapeutics Development - Nasdaq
Reston Hospital Center adds inpatient unit to expand its range of oncology services - Yahoo Finance
5 US Longevity and Anti-aging Stocks to Watch in 2025 - Investing News Network
NEW: The Most Popular Sponsored Content of 2024 - Visual Capitalist
Looking for Gold Exposure in 2025? 3 ETFs to Consider - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Stocks to Watch in 2025: PHIO, LPTH, KAVL and more - Markets.com
Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer (LPTX) - Seeking Alpha
Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts (BDTX) - Seeking Alpha
Total World Stock Index ETF Vanguard (VT-A) QuotePress Release - The Globe and Mail
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Range Cancer Therapeutics Etf (CNCR) 財務データ
Range Cancer Therapeutics Etf (CNCR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.17%
0.49%
大文字化:
|
ボリューム (24 時間):